Investigating brain tumors and metastasis treatments
Official title: Dr. Kim R50 Research Specialist Clinician 2022
Funded at University of Michigan at Ann Arbor · NIH-11057506 · Data updated 2026-11-12
This study at the University of Michigan is all about making it easier for people with brain tumors and central nervous system cancers to join clinical trials, so they can access new and potentially better treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | March 10, 2023 |
| Project end | February 29, 2028 |
| Funding year | 2025 |
| Award (this year) | $171,684 |
| NIH project number | 5R50CA276015-03 |
| Project ID | NIH-11057506 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include individuals diagnosed with brain tumors or central nervous system cancers who are seeking treatment options.
✕Less likely to help
Patients with non-cancerous brain conditions or those not diagnosed with brain tumors may not benefit from this research.
What this research studies
This research focuses on improving clinical trials for brain tumors and central nervous system cancers at the University of Michigan Rogel Cancer Center. Led by Dr. Michelle Kim, the project aims to enhance trial participation and broaden eligibility for diverse patient populations. The approach includes both interventional and observational studies, with a strong emphasis on collaboration within national cancer research networks. Patients may have the opportunity to participate in innovative treatment trials that could lead to better outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with brain tumors and metastasis.
How similar studies have gone: Previous research in similar areas has shown promising results, indicating that collaborative clinical trials can lead to significant advancements in treatment.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Kim, Michelle Miran — University of Michigan at Ann Arbor
- Study coordinator: Kim, Michelle Miran
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.